Medwave, Inc., a Danvers, Mass. company, is reporting FDA approval to market its noninvasive continuous blood pressure monitoring system, the Medwave Fusion™ (pictured below). The company calls its newly approved product “the first completely sensor-based blood pressure with vital signs options monitor.”
This marketing clearance follows up on another recent approval of the company’s product called Primo®, a portable, handheld blood pressure monitor (pictured on the right). For us, clinicians, these products seem to offer a great alternative to invasive radial a-line monitors.
From the press release:
Fusion is a non-invasive blood pressure measurement device, built around Medwave’s core sensor-based blood pressure technology, which takes readings at the wrist. Medwave’s core technology has been the subject of numerous independent clinical validation studies, and results have shown that accuracy is comparable to an invasive arterial catheter. Fusion takes Medwave’s core technology one step further by incorporating proven, sensor-based pulse oxymetry by Nellcor and thermometry by Kendall (both operating companies of Tyco Healthcare Group LP), creating a complete, non-invasive, vital signs solution.